TGFB2 and prostate carcinoma: Moreover, silibinin reduces MCP-1 and CAFs’ biomarkers (fibroblast activation protein, a-SMA, TGF-β2, vimentin, etc.), and significantly modulates the recruitment of immune cells in TME, inhibiting invasiveness in prostatic cancer (Ting et al., 2016).